Brief: Acorda Therapeutics Q3 Net Income USD -8.888 Million
13/11/2023 21:01
Nov 13 (Reuters) - Acorda Therapeutics Q3 basic EPS USD -7.16. * Q3 operating expenses USD 30.234 million * Q3 operating income USD -2.519 million * Q3 pretax profit USD -9.943 million
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease